Pulmonary hypertension in heart failure with preserved ejection fraction: A target for therapy?

Circulation

Volumn 124, Issue 2, 2011, Pages 133-135

  Waxman, Aaron B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

diastolic heart failure; Editorials; heart failure; pulmonary hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIURETIC AGENT; NITRIC OXIDE; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE V; SILDENAFIL; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; ARTERY RESISTANCE; BLOOD VESSEL COMPLIANCE; CARDIOPULMONARY HEMODYNAMICS; CORONARY ARTERY DILATATION; CORPUS CAVERNOSUM; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; EDITORIAL; ERECTILE DYSFUNCTION; HEART AFTERLOAD; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE COMPLIANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERIAL RESISTANCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RIGHT SIDED HEART DYSFUNCTION; SYSTEMIC CIRCULATION;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PREVALENCE; PURINES; RESPIRATORY FUNCTION TESTS; STROKE VOLUME; SULFONES;

EID: 79960396256     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.038885     Document Type: Editorial

References (27)

1. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008; 29:339-347. (Pubitemid 351197754)
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
3. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-327. (Pubitemid 38167688)
4. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2051-2060. (Pubitemid 351572179)
5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
6. Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJ. Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Basic Res Cardiol. 2007;102:19-27. (Pubitemid 44932768)
7. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-895. (Pubitemid 46294729)
8. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus b19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111:879-886. (Pubitemid 40279889)
9. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113: 1966-1973.
10. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007;28:233-241. (Pubitemid 46350735)
11. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53: 1119-1126.
12. Paulus WJ. Beneficial effects of nitric oxide on cardiac diastolic function: "the flip side of the coin." Heart Fail Rev. 2000;5:337-344. (Pubitemid 32000431)
13. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248. (Pubitemid 46142995)
14. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodi-esterases and regulation of smooth muscle function. Circ Res. 2003;93: 280-291. (Pubitemid 37048240)
15. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001; 65:1-52.
16. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404. (Pubitemid 28221980)
17. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43: 1149-1153. (Pubitemid 38452588)
18. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232-1240.
19. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626. (Pubitemid 30341530)
20. Tawakol A, Aziz K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, Gewirtz H. Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. Coron Artery Dis. 2005;16: 443-449. (Pubitemid 41527452)
21. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339-2348. (Pubitemid 39647608)
22. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653. (Pubitemid 46218790)
23. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003; 108:2066-2069. (Pubitemid 37337580)
24. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005; 96:1436-1440. (Pubitemid 41566628)
25. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5a prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. (Pubitemid 40321358)
26. Westermann D, Riad A, Richter U, Jager S, Savvatis K, Schuchardt M, Bergmann N, Tolle M, Nagorsen D, Gotthardt M, Schultheiss HP, Tschope C. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. 2009;104: 499-509.
27. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174.